Apnimed filed its S-1 with the SEC on July 10, 2026, but left the two numbers that matter most blank: share count and price. That’s the tell. The IPO’s whole purpose is bankrolling the launch of Oxnimbi, the sleep apnea pill sitting on the FDA’s desk, and until the agency rules, underwriters can’t price the risk.
The company already banked real money this year. Shionogi paid $100 million upfront in March for Apnimed’s half of their sleep-science joint venture, plus a $50 million milestone and royalties, freeing Apnimed to go all-in on Oxnimbi. At signing, Apnimed had $46.9 million in the bank and 65 employees.
What’s the buyer, in this case the IPO market, actually getting? A once-daily combo of aroxybutynin and atomoxetine that cut nightly breathing disruptions 46.8% versus 6.8% for placebo in the 660-patient LunAIRo trial. If cleared, it’s the first drug built specifically for OSA’s estimated 80 million U.S. sufferers, a market currently stuck wearing CPAP masks.
CEO Kevin Lind, a month into the job, ran Longboard Pharmaceuticals through its $2.6 billion sale to Lundbeck in 2024. That’s the playbook: build a single asset toward a binary event, then cash out. Apnimed’s version swaps an acquirer for public shareholders, arriving amid a hot run of biotech listings from Kailera Therapeutics and Parabilis Medicines.
No FDA decision date is disclosed in the filing, but that approval, not the roadshow, sets the real price.
Diana Kowalski